<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antiseizure medications and bone disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antiseizure medications and bone disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antiseizure medications and bone disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison M Pack, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth Shane, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah E Sellmeyer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven C Schachter, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Epilepsy is a chronic condition that affects over two million people in the United States, approximately 1 percent of the population [<a href="#rid1">1</a>]. Antiseizure medications (ASMs) remain the mainstay of treatment for epilepsy. In addition, these agents now have numerous other indications, including the treatment of migraine headaches, bipolar disorder, and chronic pain.</p><p>Both epilepsy and ASMs are associated with adverse effects on bone health. Persons with epilepsy treated with ASMs have increased rates of bone loss and abnormalities in bone and mineral metabolism [<a href="#rid2">2,3</a>]. These adverse effects may contribute to an increased risk of fracture [<a href="#rid4">4-7</a>].</p><p>This topic will review the association between ASMs and disorders of bone and mineral metabolism, including osteomalacia/rickets and osteoporosis or low bone mass. In addition, the screening, treatment, and prevention of ASM-related bone disease will be discussed.</p><p>Osteopenia, osteoporosis, and bone fractures are also a concern for children with intractable epilepsy maintained on ketogenic diets. This topic is reviewed separately. (See  <a class="medical medical_review" href="/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy", section on 'Common adverse effects'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">METABOLIC BONE DISEASE</span><span class="headingEndMark"> — </span>The first reports linking antiseizure medication (ASM) therapy to skeletal disease were published in the late 1960s [<a href="#rid8">8</a>]. Affected patients had florid bone disease with clinical, biochemical, and histologic abnormalities consistent with rickets and osteomalacia. However, these early reports included mostly institutionalized patients.</p><p>Studies of community-dwelling, ambulatory patients with epilepsy who receive ASM therapy generally describe more subtle radiographic and biochemical abnormalities, including decreased bone mineral density (BMD), abnormal vitamin D metabolism, and biochemical evidence of increased bone remodeling activity [<a href="#rid9">9-11</a>]. Each of these abnormalities is associated with decreased bone strength and increased risk of fractures compared with individuals who do not have epilepsy and do not take ASMs. Patients with epilepsy have an even higher risk for fracture, owing to the increased risk of falls and physical trauma associated with the seizures themselves, the neurologic disease that underlies the epilepsy (stroke, cerebral palsy), and the effects of certain ASMs that impair gait stability. Thus, the identification of individuals with epilepsy who are predisposed to fracture because of decreased bone strength is an important aspect of their management.</p><p class="headingAnchor" id="H3"><span class="h2">Osteoporosis</span><span class="headingEndMark"> — </span>Osteoporosis is defined as a skeletal disorder characterized by decreased bone strength leading to an increased risk of fracture. Bone strength represents the integration of the amount of bone present (bone mass or density) and the quality of that bone [<a href="#rid12">12</a>]. Although fractures are the only clinical symptom of osteoporosis, osteoporosis may be diagnosed radiographically before fractures occur by measuring the amount of bone present (bone mineral density or BMD). (See  <a class="medical medical_review" href="/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"</a>.)</p><p>Osteoporosis, whether manifested by low BMD or fractures, is most common in postmenopausal women and older men, in whom the effects of aging (estrogen and testosterone deficiency) cause bone to be lost more rapidly than it can be restored. This leads to deterioration of the bone microarchitecture and associated reductions in strength.</p><p>However, osteoporosis can also develop as a result of a host of underlying medical conditions and medications, in which case it is termed secondary osteoporosis. Concomitantly occurring secondary causes of osteoporosis can increase the severity of osteoporosis in postmenopausal women and older men and can cause osteoporosis in young men, women, and children. ASMs are one of the classes of medications associated with secondary osteoporosis  (<a class="graphic graphic_table graphicRef54926" href="/d/graphic/54926.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. In a murine study of untreated chronic temporal lobe epilepsy, there was no evidence of overt bone abnormalities due to epilepsy itself [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/2049.html" rel="external">"Etiology of osteoporosis in men"</a> and  <a class="medical medical_review" href="/d/html/2058.html" rel="external">"Epidemiology and etiology of premenopausal osteoporosis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h3">Fracture</span><span class="headingEndMark"> — </span>Fracture is the most important manifestation of osteoporosis. Several studies have reported that fracture rates are higher in patients with epilepsy than in control populations, and among patients with epilepsy, fractures are more common in postmenopausal women and older men [<a href="#rid4">4-7,15-20</a>].</p><p>In a report from the Women's Health Initiative (WHI) study, which included 1385 users of ASMs and 137,282 nonusers aged 50 to 79 years followed for a mean of 7.7 years, use of ASMs was associated with a significantly increased risk of total fractures (annualized percentage 3.35 versus 2.10 percent, hazard ratio [HR] 1.44, 95% CI 1.30-1.61) and site-specific fractures, including hip fracture (0.29 versus 0.15 percent, HR 1.51, 95% CI 1.05-2.17) and clinical vertebral fracture (0.48 versus 0.22 percent, HR 1.60, 95% CI 1.20-2.12) [<a href="#rid21">21</a>]. Both the number of ASMs used in a patient (more than one ASM compared with one) and type (enzyme inducing versus non-enzyme inducing) were significantly associated with fracture risk. (See <a class="local">'Effect of ASM type'</a> below.)</p><p>Other factors associated with higher fracture risk in adults with epilepsy in some [<a href="#rid16">16,22</a>], but not all [<a href="#rid23">23,24</a>], studies include older age, female sex, greater severity of epilepsy, and duration of ASM use. Children and young adults may also have an increased risk of fractures compared with controls [<a href="#rid25">25</a>]. For example, a case-control study of 23 pairs of siblings aged 5 to 18 years who were within two years of age and who were ASM exposure-discordant found that the siblings taking ASMs reported more fractures (15 fractures in 8 subjects treated with ASMs compared with 4 fractures in 3 controls) and had reductions in tibial volumetric BMD and lower limb muscle force compared with their matched controls [<a href="#rid26">26</a>]. Another study found an age effect among new ASM users with increased nontraumatic fracture incidence in a younger age group peaking at 11 to 13 years then decreasing with older age group [<a href="#rid27">27</a>].</p><p>Several observations indicate that the increase in fracture rate is related to seizure-related injuries and the effects of certain ASMs that impair gait stability, as well as the adverse effects of ASMs on bone strength:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with generalized tonic-clonic seizures are at higher risk for fracture than patients with partial seizures, suggesting that seizure-related injuries contribute [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The observation that epilepsy was associated with an even higher relative risk (RR) of hip versus forearm fracture (5.3 versus 1.7) suggests a possible preponderance of falls occurring in patients unable to use their hand to break the fall, a situation that might occur during a seizure [<a href="#rid10">10,16,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the WHI study, there was a significant association between ASM use and the risk of falls (HR 1.6, 95% CI 1.5-1.7) [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a longitudinal study of balance measures and lower limb strength in 26 sibling pairs, chronic ASM users had poorer balance compared with nonusers [<a href="#rid29">29</a>]. There was no difference in quadriceps muscle strength.</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Bone mineral density</span><span class="headingEndMark"> — </span>Some ASMs alter bone and mineral metabolism. Several studies have reported low BMD at multiple sites in adult patients receiving ASMs, with measurements generally ranging between 10 and 16 percent below controls [<a href="#rid9">9,19,30-34</a>]. Men and women appear to be affected similarly [<a href="#rid34">34</a>]. A meta-analysis of 12 studies measuring BMD in patients with epilepsy found an overall significant deficit of BMD in both hip and spine with mean Z-score deviations of -0.56 and -0.38, respectively [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry", section on 'DXA technology'</a>.)</p><p>In contrast, however, a cross-sectional study of premenopausal women found BMD to be normal despite ASM monotherapy for an average of 8 to 13 years [<a href="#rid35">35</a>]. In children, reduced BMD at axial and appendicular sites has been described but not as consistently as in older adults [<a href="#rid32">32,36-45</a>]. Increasing age is associated with decreased BMD among patients using ASMs, perhaps contributing to these discrepancies [<a href="#rid30">30,33</a>]. Other potential confounders include body mass index (BMI), number and type of ASMs, and duration of treatment [<a href="#rid32">32,46</a>]. (See <a class="local">'Effect of ASM type'</a> below.)</p><p>Most [<a href="#rid36">36,37,44,47</a>], but not all [<a href="#rid30">30</a>], cross-sectional studies demonstrate that duration of ASM treatment is associated with the degree of BMD loss. In some prospective studies, progressive bone loss occurred over time [<a href="#rid9">9,33,48</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 81 men aged 25 to 54 years, followed for 12 to 29 months, there was a 1.8 percent annualized loss of BMD by dual-energy x-ray absorptiometry (DXA), much higher than would be expected in men of this age [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of older women followed prospectively for an average of 4.4 years, the rate of bone loss at the total hip (after adjusting for confounders) was -0.70 percent per year in 4094 non-ASM users, -0.87 percent per year in 61 intermittent ASM users, and -1.16 percent per year in 41 continuous ASM users [<a href="#rid48">48</a>].</p><p></p><p>In contrast, in the subset of ASM users (84 women) in the WHI study who had BMD measured prospectively, there was no significant difference in three-year change in BMD of the hip, spine, or total body between users and nonusers of ASMs [<a href="#rid21">21</a>]. The small number of women who had BMD measured, combined with the fact that many ASM users were taking hormone therapy, may have reduced the ability of the study to show an association between ASM use and change in BMD. Alternatively, these observations may indicate that the increase in fracture rate may be due to seizure-related injuries and the effects of certain ASMs that impair gait stability rather than the adverse effects of ASMs on bone strength alone.</p><p class="headingAnchor" id="H6"><span class="h3">Markers of bone turnover</span><span class="headingEndMark"> — </span>Markers of bone formation and resorption, measured in the serum and urine, may be elevated in adults with epilepsy receiving ASMs. Elevated levels have been reported during long-term ASM therapy [<a href="#rid31">31,40,48,49</a>], and increases have been reported to occur after initiation of ASM therapy [<a href="#rid31">31,35,40,48-51</a>]. Elevated bone turnover markers are considered to reflect increased bone remodeling activity, are associated with higher rates of bone loss, and are independent predictors of fracture. (See  <a class="medical medical_review" href="/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis"</a>.)</p><p>Findings in adults with epilepsy include:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased serum alkaline phosphatase activity in adults receiving some ASMs [<a href="#rid49">49,50,52-54</a>]. In those studies that measured isoenzymes of alkaline phosphatase, the increase in total alkaline phosphatase activity appeared to be related to increases in the bone isoenzyme fraction [<a href="#rid35">35,55,56</a>]. <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> has been associated with the most consistent and marked elevations of alkaline phosphatase. However, increases have also been reported with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>. (See <a class="local">'Effect of ASM type'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High serum levels of other bone formation markers. High levels of osteocalcin and C-terminal extension peptide of type I procollagen (PICP) have been described in persons receiving ASMs [<a href="#rid31">31,40,49-51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated markers of bone resorption. C-terminal telopeptide of human type I collagen (CTX) and cross-linked N-terminal telopeptides of type I collagen (NTX) are also elevated in patients treated with ASMs [<a href="#rid31">31,49-51</a>].</p><p></p><p>While bone turnover markers are not used to diagnose osteoporosis because values overlap substantially in normal subjects and patients with osteoporosis, the collective data suggest that bone remodeling activity is higher in patients taking ASMs. (See  <a class="medical medical_review" href="/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Osteomalacia and rickets</span><span class="headingEndMark"> — </span>Osteomalacia is a disorder of bone mineralization in which the deposition of calcium and phosphate into newly formed bone matrix (osteoid) at sites of bone remodeling or periosteal or endosteal apposition is either insufficient or completely absent. On histologic examination, thickened layers of unmineralized osteoid cover a higher than normal proportion of the bone surface.</p><p>Clinically, patients with osteomalacia complain of bone pain, which is particularly prominent in the lower extremities and is exacerbated by weightbearing. They may also notice muscle weakness, particularly of the upper arms and thighs. Physical examination often reveals tenderness to pressure over the anterior tibiae, an antalgic gait, and proximal muscle weakness. Although there are many causes of osteomalacia, when osteomalacia occurs in association with ASM treatment, it is generally associated with profound vitamin D deficiency. Serum calcium and phosphorous and serum 25-hydroxyvitamin D (25[OH]D) may be low, and parathyroid hormone (PTH) levels and total alkaline phosphatase activity may be elevated. (See  <a class="medical medical_review" href="/d/html/2045.html" rel="external">"Epidemiology and etiology of osteomalacia"</a>.)</p><p>Rickets, a failure of or delay in mineralization of cartilage at growth plates, occurs only in children and results in profusion of disorganized, nonmineralized, degenerating cartilage and consequent widening of the epiphyseal plates with flaring or cupping and irregularity of the epiphyseal-metaphyseal junctions. If untreated, the disorder may progress to include bowing of the lower extremities. In adults, joint enlargement due to the profusion of cartilage and ultimate formation of excess but undermineralized bone is sometimes evident [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/5856.html" rel="external">"Overview of rickets in children"</a>.)</p><p>As noted above, early reports of bone disease in patients with epilepsy describe osteomalacia [<a href="#rid8">8,58,59</a>]. However, these reports primarily included institutionalized patients, and in ambulatory, community-dwelling persons with epilepsy, osteomalacia is rarely seen today.</p><p>Bone biopsy studies in patients taking ASMs found normal osteoid seam width and mineralization rates that were consistently normal or increased [<a href="#rid60">60,61</a>]. These results are not consistent with osteomalacia and suggest that bone disease associated with ASM use is a disorder of increased remodeling (consistent with bone turnover markers data) rather than abnormal mineralization, resulting in osteoporosis rather than osteomalacia. Similarly, while rickets has been reported in older studies of children treated with ASMs, most of the subjects were institutionalized, and the findings likely reflect the additive effects of ASM and lack of sun exposure on vitamin D metabolism [<a href="#rid62">62</a>]. More recent studies of ambulatory, community-dwelling children taking ASMs do not report clinical rickets [<a href="#rid36">36-39</a>].</p><p class="headingAnchor" id="H8"><span class="h1">EFFECT OF ASM TYPE</span><span class="headingEndMark"> — </span>The relationship between antiseizure medication (ASM) type and fracture risk remains uncertain. In a systematic review of 13 observational studies in patients with epilepsy that compared treatment with ASMs that induce the cytochrome P450 system versus ASMs that do not induce, five studies showed decreased bone mineral density (BMD) in users of ASMs that induce the cytochrome P450 system, whereas five studies showed no effect on BMD [<a href="#rid63">63</a>]. Two studies showed an increased risk of fracture in patients treated with enzyme-inducing ASMs, whereas one study showed no difference in fracture risk. In the largest study, a prospective study of over 63,000 patients with epilepsy, there was an increased risk of hip fracture with use of enzyme-inducing compared with non-enzyme-inducing ASMs for both men (hazard ratio [HR] 1.53, 95% CI 1.10-2.12) and women (HR 1.49, 95% CI 1.15-1.94) [<a href="#rid64">64</a>].</p><p>Induction of the cytochrome P450 system by ASMs leads to increased catabolism of vitamin D to inactive metabolites and a subsequent rise in parathyroid hormone (PTH), which increases the mobilization of bone calcium stores and subsequent bone turnover [<a href="#rid52">52,65-67</a>]. However, this mechanism does not account for the studies that have shown accelerated bone turnover or bone loss independent of vitamin D deficiency [<a href="#rid32">32,33,35,49-51,61</a>].</p><p>Other mechanisms that have been implicated in the pathogenesis of ASM-induced bone disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>A cytochrome P450-induced increase in metabolism of sex steroids, resulting in lower estrogen levels [<a href="#rid68">68</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>A direct inhibitory effect of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> on intestinal absorption of calcium [<a href="#rid69">69,70</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperparathyroidism with normal serum 25-hydroxyvitamin D (25[OH]D) level [<a href="#rid49">49</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Direct effects of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> to stimulate osteoclastic bone resorption [<a href="#rid71">71</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Direct effects of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> to inhibit proliferation of human osteoblast-like cells at concentrations equivalent to therapeutic doses for the treatment of epilepsy [<a href="#rid47">47</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin K deficiency [<a href="#rid72">72</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Calcitonin deficiency [<a href="#rid73">73</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated homocysteine levels [<a href="#rid74">74</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Suppression of long bone growth by <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> by inhibiting cartilage formation and accelerating ossification of the growth plate [<a href="#rid75">75</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic factors [<a href="#rid76">76,77</a>]</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Enzyme inducing</span><span class="headingEndMark"> — </span>The ASMs most commonly associated with altered bone and mineral metabolism and decreased bone density are those that induce the cytochrome P450 enzyme system [<a href="#rid35">35-37,48-53</a>]. The ASMs that induce the cytochrome P450 enzyme system are <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 2</a>) [<a href="#rid31">31,35,37,48,49,52,53</a>]. (See  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p>Induction of the cytochrome P450 system by ASMs leads to increased catabolism of vitamin D to inactive metabolites [<a href="#rid52">52,65-67</a>]. Decreased availability of active vitamin D metabolites leads, in turn, to decreased gastrointestinal absorption of calcium, hypocalcemia, and a rise in circulating PTH. PTH increases the mobilization of bone calcium stores and subsequent bone turnover. This mechanism is the one most often purported to underlie the bone disease associated with ASM use.</p><p>Laboratory findings in patients taking these drugs often, but not consistently, include hypocalcemia, hypophosphatemia, reduced serum 25(OH)D levels, elevated PTH levels, and elevated markers of bone formation and resorption. All of these have been described in adults taking enzyme-inducing ASMs [<a href="#rid52">52,53,55,56,78-82</a>].</p><p>Basic studies have evaluated the effect of these ASMs on the expression of specific cytochrome P450 isoenzymes involved in vitamin D metabolism [<a href="#rid83">83,84</a>]. <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">Phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> are among a class of drugs known as xenobiotics. Xenobiotics activate a nuclear receptor known as either the steroid and xenobiotic receptor (SXR) or pregnane X receptor (PXR):</p><p class="bulletIndent1"><span class="glyph">●</span>One study found that xenobiotics upregulate 25(OH)D3-24-hydroxylase (CYP24) in the kidney through activation of PXR [<a href="#rid84">84</a>]. This enzyme catalyzes the conversion of 25(OH)D to its inactive metabolite (24,25-dihydroxyvitamin).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other investigators found that xenobiotic activation of PXR did not upregulate CYP24 but did increase expression of a different isoenzyme, CYP3A4, in the liver and small intestine [<a href="#rid83">83</a>]. This enzyme converts vitamin D to more polar inactive metabolites. They also found that xenobiotic activation of PXR represses CYP24 expression in the liver and intestine, suggesting a dual role in mediating vitamin D metabolism.</p><p></p><p>Studies that have compared ASM regimens often find that <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> is associated with the most marked increases in bone turnover markers and decreases in BMD [<a href="#rid31">31,35,48,49,85</a>]. In a prospective study of premenopausal women with epilepsy receiving a single ASM, treatment with phenytoin for one year was associated with a 2.6 percent decrease in femoral neck BMD, whereas treatment with other ASMs (<a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>) did not have such an adverse effect on BMD [<a href="#rid85">85</a>]. In a prospective cohort study of 90 young Thai adults, patients who stopped or switched phenytoin to <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> had a significant increase in BMD at multiple sites as well as an increase in 25(OH)D concentrations [<a href="#rid86">86</a>]. In contrast, patients who continued phenytoin had a significant decrease in BMD at multiple sites and a decrease in 25(OH)D concentrations. Animal studies suggest that phenytoin may also have direct toxicity on bone [<a href="#rid47">47,71</a>].</p><p><a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> appears to be less commonly associated with bone disease than <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>. While hypocalcemia, hypophosphatemia, decreased vitamin D metabolites, and elevated markers of bone turnover have all been reported with carbamazepine, these findings have not been observed as consistently [<a href="#rid11">11,36,41,42,50,51</a>]. One short-term (10-week) study of normal, young men found that carbamazepine was not associated with any change in markers of bone turnover [<a href="#rid87">87</a>]. In contrast, significant increases in markers of bone turnover were documented in children and adolescents after initiation of carbamazepine treatment for epilepsy [<a href="#rid50">50,51</a>].</p><p>Bone mass has been reported to be normal or decreased in children and young adults treated with long-term <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> therapy [<a href="#rid32">32,42,49,88,89</a>]. In a prospective study of premenopausal women with epilepsy receiving a single ASM, treatment with carbamazepine was not associated with any changes in markers of bone turnover or BMD [<a href="#rid85">85</a>]. However, fracture risk has been reported to be increased in adults treated with carbamazepine [<a href="#rid5">5</a>].</p><p>In a meta-analysis of 87 studies evaluating bone health indices in carbamazepine-treated persons compared with controls, vitamin D levels as well as calcium were significantly lower and alkaline phosphatase was higher in carbamazepine-treated persons with epilepsy. Interestingly, there was no difference in BMD [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Non-enzyme inducing</span></p><p class="headingAnchor" id="H11"><span class="h3">Valproate</span><span class="headingEndMark"> — </span>In contrast to <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> is an inhibitor of the cytochrome P450 enzyme system. (See  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p>Although studies published in the 1980s did not find any association with bone disease [<a href="#rid52">52,78</a>], subsequent studies have consistently reported bone loss, abnormal biochemical indices of bone and mineral metabolism, and higher fracture rates with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> in both children and adults [<a href="#rid5">5,31,36,39,40</a>]. Both dose and duration of valproate therapy have been associated with increased rates of bone loss and higher incidence of fracture [<a href="#rid5">5,40</a>].</p><p>Three meta-analyses support negative effects of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> on children and adults with epilepsy [<a href="#rid91">91-93</a>]. BMD reductions and increased serum alkaline phosphatase were seen in children and adults. Reduced vitamin D and calcium levels and increased PTH occurred in children and not adults with epilepsy.</p><p>In cell-culture studies, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> has been shown to suppress longitudinal bone growth by inhibiting cartilage formation and accelerating ossification of the growth plate [<a href="#rid75">75</a>]. Similarly, valproate-treated rats have decreased bone volume fraction and decreased apparent density [<a href="#rid94">94</a>]. Perhaps consistent with this effect, short stature has been reported in children treated with valproate [<a href="#rid39">39</a>]. In the same study, low BMD, short stature, and elevated markers of bone turnover were more pronounced in children treated with valproate in combination with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> [<a href="#rid39">39</a>]. In this study, physical inactivity was identified as a possible confounder.</p><p class="headingAnchor" id="H12"><span class="h3">Other ASMs</span><span class="headingEndMark"> — </span>Few studies have evaluated the effect of newer antiseizure medications (ASMs) on bone and mineral metabolism and BMD:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lamotrigine</strong> – <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> is increasingly used to treat epilepsy. A study of premenopausal women on ASM monotherapy (<a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, or lamotrigine) found no significant effect of lamotrigine on BMD, calciotropic hormones, or bone turnover markers [<a href="#rid35">35,85</a>]. Although treatment duration was shorter for patients on lamotrigine, there was no association between duration of therapy and BMD or any marker of bone and mineral metabolism. Similarly, 32 adults with newly diagnosed epilepsy treated with lamotrigine had no changes in markers of bone turnover after two years [<a href="#rid95">95</a>] and eight Korean men and women did not have any changes in BMD after six months of treatment with lamotrigine [<a href="#rid89">89</a>]. In contrast, children treated with lamotrigine were significantly shorter and had lower BMD and higher markers of bone turnover compared with children not receiving ASMs [<a href="#rid39">39</a>]. These findings were most pronounced in children treated with both lamotrigine and valproate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxcarbazepine</strong> – A large case-control study found that <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> (and <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a>) were among the ASMs associated with small increases in the relative risk (RR) of fracture after controlling for epilepsy diagnosis [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">A study of 45 patients found reduced serum 25(OH)D and slightly elevated osteocalcin levels among patients taking <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> [<a href="#rid11">11</a>]. A retrospective claims-based study found that initiating oxcarbazepine among 4 to 13 year olds was associated with an elevated risk of fragility fracture [<a href="#rid96">96</a>]. Among children with new-onset focal epilepsy treated with oxcarbazepine, serum calcium was reduced and parathyroid hormone levels were increased [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Levetiracetam</strong> – A study of 61 patients (mean age 31 years) initiating <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> found no adverse effect on BMD or in biochemical markers (25[OH]D, calcium, phosphorus, PTH, markers of bone remodeling) after 14 months of treatment [<a href="#rid98">98</a>]. Among 25 children with new-onset focal epilepsy treated with levetiracetam, there was no effect of levetiracetam on bone metabolism [<a href="#rid97">97</a>]. Similarly, 47 adults with newly diagnosed epilepsy treated with levetiracetam had no changes in markers of bone turnover after two years [<a href="#rid95">95</a>]. In another study, there was improvement in BMD two years after switching from <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> to levetiracetam [<a href="#rid86">86</a>]. A retrospective claims-based study found that initiating levetiracetam among 4 to 13 year olds did not increase the risk of fragility fracture [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topiramate</strong><strong> and </strong><strong>zonisamide</strong> – <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> and <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a> are carbonic anhydrase inhibitors. As carbonic anhydrase inhibitors are potent inhibitors of osteoclastic bone resorption, one might expect lower rates of bone loss to be associated with their use [<a href="#rid99">99</a>]. Limited data suggest no effect on BMD. As an example, in a cross-sectional study in premenopausal women with epilepsy, there were no differences in BMD Z-scores or vitamin D metabolites in women taking topiramate compared with control women and compared with women taking <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a> [<a href="#rid100">100</a>]. Topiramate was associated with lower PTH, bicarbonate, and calcium concentrations as well as higher biochemical markers of bone turnover compared with the other groups. In a prospective study in 59 adults with new onset epilepsy, there were no changes in BMD or biochemical markers of bone turnover after 13 months of treatment with zonisamide [<a href="#rid101">101</a>]. </p><p></p><p class="headingAnchor" id="H13"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>Osteoporosis screening is typically recommended in postmenopausal women and older men with risk factors for fracture  (<a class="graphic graphic_table graphicRef76445" href="/d/graphic/76445.html" rel="external">table 3</a>) (see  <a class="medical medical_review" href="/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a>). For patients with epilepsy, we consider the risk factors for bone disease related to antiseizure medication (ASM) use in addition to more general risk factors for osteoporosis and fracture.</p><p class="headingAnchor" id="H14"><span class="h2">Clinical risk factor assessment</span><span class="headingEndMark"> — </span>Risk factors for bone disease in ASM users include high-dose, multidrug regimens; long-term therapy; inadequate intakes of vitamin D; limited sunlight exposure; chronic illness; old age; institutionalization; low physical activity; adjuvant therapy to induce chronic metabolic acidosis (<a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> or ketogenic diets); and concomitant therapy with other drugs that induce hepatic enzymes (<a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, glutethimide).</p><p>Risk factors for osteoporosis and fractures include female sex, postmenopausal status, old age, poor balance, tobacco, low body mass index (BMI), and low dietary calcium and vitamin D intake  (<a class="graphic graphic_table graphicRef76445" href="/d/graphic/76445.html" rel="external">table 3</a>). ASMs are an accepted secondary cause of osteoporosis. (See  <a class="medical medical_review" href="/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Bone mineral density</span><span class="headingEndMark"> — </span>It is reasonable to recommend measuring bone mineral density (BMD) in patients with epilepsy who have risk factors for osteoporosis and risk factors for ASM-related bone disease, as well as in patients who have experienced a fragility fracture. Persons treated with long-term (&gt;5 years) enzyme-inducing ASMs or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> are likely at risk and therefore should be screened.</p><p>In a person with a normal baseline BMD, the frequency of testing should depend upon the age and sex of the patient. More frequent testing (every two years) is appropriate in a postmenopausal woman or older man and less frequent in a premenopausal woman or young man. Because multiple risk factors further increase risk of fracture, earlier and more frequent screening is prudent in such patients  (<a class="graphic graphic_table graphicRef54926" href="/d/graphic/54926.html" rel="external">table 1</a>) [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>In patients with epilepsy who are taking ASMs, we typically measure serum calcium, phosphate, and 25-hydroxyvitamin D (25[OH]D) levels [<a href="#rid46">46,102-104</a>].</p><p class="headingAnchor" id="H17"><span class="h1">TREATMENT AND PREVENTION</span><span class="headingEndMark"> — </span>Few studies have rigorously evaluated strategies for prevention and treatment of bone disease associated with antiseizure medications (ASMs).</p><p class="headingAnchor" id="H18"><span class="h2">Lifestyle measures</span><span class="headingEndMark"> — </span>Patients with epilepsy who are taking ASMs should adopt the same lifestyle measures that are recommended for all patients at risk for osteoporosis and fracture. These include regular weightbearing exercise, smoking cessation, limiting alcohol intake, and preventing falls. In one study, however, adults with epilepsy did not engage in higher level of osteoprotective behaviors and were less physically active when compared with persons without epilepsy [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Lifestyle measures to reduce bone loss'</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Lifestyle measures'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Calcium and vitamin D</span><span class="headingEndMark"> — </span>As a general rule, patients should achieve the reference calcium intake for their age group  (<a class="graphic graphic_table graphicRef71669" href="/d/graphic/71669.html" rel="external">table 4</a>) through diet and supplements (if needed) and receive supplemental vitamin D (400 to 800 international units/day).</p><p>Because studies have shown that much higher doses (up to 4000 international units) may be necessary to normalize serum levels of 25-hydroxyvitamin D (25[OH]D) in some patients, we typically measure serum 25(OH)D levels to determine whether vitamin D intake is sufficient to maintain levels above 30 ng/mL [<a href="#rid106">106-108</a>]. This is particularly important in the case of older adults or institutionalized patients who may have limited access to sunshine.</p><p>There are limited data on the optimal doses of calcium and vitamin D for patients with epilepsy who are taking ASMs. In a study that included both institutionalized and ambulatory individuals receiving ASMs who had low baseline serum 25(OH)D levels, vitamin D supplementation was titrated to achieve a normal serum 25(OH)D concentration [<a href="#rid109">109</a>]. All achieved normal 25(OH)D levels over a period of 12 to 15 months. Dose requirements ranged from 400 to 4000 international units daily.</p><p>In two randomized trials in adults and children given either low-dose vitamin D (400 international units/day) or high-dose vitamin D (4000 international units/day in adults and 2000 international units/day in children), there were no significant differences in bone mineral density (BMD) at one year between the adult groups, although BMD had increased from baseline in the high-dose group only [<a href="#rid106">106</a>]. In children, both dose groups had comparable increases in BMD after one year.</p><p>In a systematic review of nine studies evaluating vitamin D supplementation in adults with epilepsy, vitamin D treatment increased serum calcium in three of eight studies, decreased alkaline phosphatase in six of eight studies, and decreased parathyroid hormone (PTH) in two of four studies [<a href="#rid110">110</a>]. All six studies that investigated BMD had significant findings; however, likely due to varying methodologies employed by the studies, the impact of vitamin D on BMD was not conclusive.</p><p class="headingAnchor" id="H20"><span class="h2">Pharmacologic therapy</span><span class="headingEndMark"> — </span>In the absence of adequate data specifically targeting osteoporosis in individuals treated with ASMs, treatment recommendations should follow other guidelines, such as for postmenopausal women and men (see  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a>). However, it is of particular importance to make certain that individuals receiving ASMs are vitamin D replete before initiating therapy for osteoporosis.</p><p>In a two-year, double-blind trial evaluating <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> or placebo (all patients received calcium and vitamin D supplementation) in 80 male veterans with epilepsy treated with either <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, there was a greater increase in lumbar spine BMD in the risedronate group (0.065 versus 0.016 g/cm<sup>2</sup> in the placebo group) [<a href="#rid111">111</a>]. There were fewer new vertebral fractures in the risedronate group (none versus five in the placebo group).</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fracture risk</strong> – Patients with epilepsy are at higher risk for fracture because of a higher risk for falls and physical trauma related to seizures themselves, the neurologic disease that underlies the epilepsy (stroke, cerebral palsy), and the effects of certain antiseizure medications (ASMs) that impair gait stability and alter bone and mineral metabolism. (See <a class="local">'Fracture'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of ASM type on fracture risk and bone loss</strong> – The relationship between ASM type and fracture risk remains uncertain. However, ASMs that induce the hepatic cytochrome P450 enzyme system (<a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>) are those most commonly implicated as affecting bone and mineral metabolism  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 2</a>). The most commonly implicated pathogenetic mechanism is via accelerated catabolism of vitamin D. In addition, there is growing evidence to suggest that <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, a cytochrome P450 enzyme inhibitor, also affects bone and mineral metabolism. There are limited data available on the skeletal effects of newer ASMs, such as <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>. (See <a class="local">'Effect of ASM type'</a> above.)</p><p></p><p class="bulletIndent1">Several additional mechanisms for ASM-associated bone loss have been proposed, including direct effects on intestinal calcium absorption and also on osteoblasts and osteoclasts. It is likely that more than one mechanism contributes to ASM-associated bone disease and that these are, to some extent, specific to the particular ASM. (See <a class="local">'Effect of ASM type'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – For individuals with a history of prolonged use (&gt;5 years) of ASMs, especially those using enzyme-inducing ASMs or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, those with other risk factors for ASM-induced bone disease (high-dose, multidrug regimens; low vitamin D intake; limited sunlight exposure; chronically ill, older, or institutionalized patients; low physical activity levels; exposure to drugs that induce chronic metabolic acidosis; and concomitant therapy with other drugs that induce hepatic enzymes), and those with history of fragility fracture or additional risk factors for osteoporosis, we suggest bone mineral density (BMD) testing (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium and vitamin D intake</strong> – For patients receiving ASMs, we suggest calcium and vitamin D supplementation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Although the optimal intake (diet plus supplement) has not been clearly established in this patient population, the age group-based reference intake for calcium  (<a class="graphic graphic_table graphicRef71669" href="/d/graphic/71669.html" rel="external">table 4</a>) and 800 international units of vitamin D daily are the typical doses used. However, patients receiving ASMs, particularly enzyme-inducing ASMs, may require higher doses of vitamin D. We typically measure serum 25-hydroxyvitamin D (25[OH]D) levels in such patients to determine whether vitamin D intake is sufficient to maintain levels within the normal range. (See <a class="local">'Calcium and vitamin D'</a> above and  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a> and  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Vitamin D replacement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic therapy</strong> – The pharmacologic treatment of osteoporosis and fracture in patients taking ASMs is the same as the treatment of osteoporosis in individuals not on ASM therapy. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a> and  <a class="medical medical_review" href="/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34:453.</a></li><li><a class="nounderline abstract_t">Pack AM. Bone disease in epilepsy. Curr Neurol Neurosci Rep 2004; 4:329.</a></li><li><a class="nounderline abstract_t">Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004; 5 Suppl 2:S24.</a></li><li><a class="nounderline abstract_t">Vestergaard P, Tigaran S, Rejnmark L, et al. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999; 99:269.</a></li><li><a class="nounderline abstract_t">Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45:1330.</a></li><li><a class="nounderline abstract_t">Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.</a></li><li><a class="nounderline abstract_t">Desai KB, Ribbans WJ, Taylor GJ. Incidence of five common fracture types in an institutional epileptic population. Injury 1996; 27:97.</a></li><li><a class="nounderline abstract_t">Kruse R. [Osteopathies in antiepileptic long-term therapy (preliminary report)]. Monatsschr Kinderheilkd 1968; 116:378.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Walczak TS, Blackwell TL, et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008; 71:723.</a></li><li><a class="nounderline abstract_t">Vestergaard P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand 2005; 112:277.</a></li><li><a class="nounderline abstract_t">Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006; 47:510.</a></li><li><a class="nounderline abstract_t">NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785.</a></li><li><a class="nounderline abstract_t">Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006; 12:436.</a></li><li><a class="nounderline abstract_t">Brady RD, Wong KR, Robinson DL, et al. Bone Health in Rats With Temporal Lobe Epilepsy in the Absence of Anti-Epileptic Drugs. Front Pharmacol 2019; 10:1278.</a></li><li><a class="nounderline abstract_t">Jaglal SB, Kreiger N, Darlington GA. Lifetime occupational physical activity and risk of hip fracture in women. Ann Epidemiol 1995; 5:321.</a></li><li><a class="nounderline abstract_t">Souverein PC, Webb DJ, Petri H, et al. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005; 46:304.</a></li><li><a class="nounderline abstract_t">Tsiropoulos I, Andersen M, Nymark T, et al. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 2008; 49:2092.</a></li><li><a class="nounderline abstract_t">Jetté N, Lix LM, Metge CJ, et al. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 2011; 68:107.</a></li><li><a class="nounderline abstract_t">Beerhorst K, van der Kruijs SJ, Verschuure P, et al. Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. J Neurol Sci 2013; 331:19.</a></li><li><a class="nounderline abstract_t">Shen C, Chen F, Zhang Y, et al. Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone 2014; 64:246.</a></li><li><a class="nounderline abstract_t">Carbone LD, Johnson KC, Robbins J, et al. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). J Bone Miner Res 2010; 25:873.</a></li><li><a class="nounderline abstract_t">Souverein PC, Webb DJ, Weil JG, et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006; 66:1318.</a></li><li><a class="nounderline abstract_t">Koppel BS, Harden CL, Nikolov BG, Labar DR. An analysis of lifetime fractures in women with epilepsy. Acta Neurol Scand 2005; 111:225.</a></li><li><a class="nounderline abstract_t">Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002; 43:768.</a></li><li><a class="nounderline abstract_t">Sheth RD. Bone health in pediatric epilepsy. Epilepsy Behav 2004; 5 Suppl 2:S30.</a></li><li><a class="nounderline abstract_t">Simm PJ, Seah S, Gorelik A, et al. Impaired bone and muscle development in young people treated with antiepileptic drugs. Epilepsia 2017; 58:1931.</a></li><li><a class="nounderline abstract_t">Whitney DG, Kalia V, Rajapakse CS, et al. The effect of age when initiating anti-seizure medication therapy on fragility fracture risk for children with epilepsy. Bone 2021; 149:115996.</a></li><li><a class="nounderline abstract_t">Annegers JF, Melton LJ 3rd, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia 1989; 30:348.</a></li><li><a class="nounderline abstract_t">Shiek Ahmad B, Wark JD, Petty SJ, et al. Changes in balance function with chronic antiepileptic drug therapy: A twin and sibling study. Epilepsia 2015; 56:1714.</a></li><li><a class="nounderline abstract_t">Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999; 8:339.</a></li><li><a class="nounderline abstract_t">Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001; 57:445.</a></li><li><a class="nounderline abstract_t">Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58:1348.</a></li><li><a class="nounderline abstract_t">Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002; 59:781.</a></li><li><a class="nounderline abstract_t">Pack AM, Olarte LS, Morrell MJ, et al. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003; 4:169.</a></li><li><a class="nounderline abstract_t">Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005; 57:252.</a></li><li><a class="nounderline abstract_t">Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995; 127:256.</a></li><li><a class="nounderline abstract_t">Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994; 16:382.</a></li><li><a class="nounderline abstract_t">Tsukahara H, Kimura K, Todoroki Y, et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002; 44:247.</a></li><li><a class="nounderline abstract_t">Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001; 42:1141.</a></li><li><a class="nounderline abstract_t">Oner N, Kaya M, Karasalihoğlu S, et al. Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health 2004; 40:470.</a></li><li><a class="nounderline abstract_t">Akin R, Okutan V, Sarici U, et al. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998; 19:129.</a></li><li><a class="nounderline abstract_t">Erbayat Altay E, Serdaroğlu A, Tümer L, et al. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000; 13:933.</a></li><li><a class="nounderline abstract_t">Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006; 35:177.</a></li><li><a class="nounderline abstract_t">Sheth RD, Binkley N, Hermann BP. Progressive bone deficit in epilepsy. Neurology 2008; 70:170.</a></li><li><a class="nounderline abstract_t">Coppola G, Fortunato D, Auricchio G, et al. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 2009; 50:2140.</a></li><li><a class="nounderline abstract_t">Heller HJ, Sakhaee K. Anticonvulsant-induced bone disease: a plea for monitoring and treatment. Arch Neurol 2001; 58:1352.</a></li><li><a class="nounderline abstract_t">Feldkamp J, Becker A, Witte OW, et al. Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000; 108:37.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Walczak TS, Blackwell T, et al. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004; 62:2051.</a></li><li><a class="nounderline abstract_t">Välimäki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994; 9:631.</a></li><li><a class="nounderline abstract_t">Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000; 47:385.</a></li><li><a class="nounderline abstract_t">Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002; 43:1488.</a></li><li><a class="nounderline abstract_t">Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 1986; 59:569.</a></li><li><a class="nounderline abstract_t">O'Hare JA, Duggan B, O'Driscoll D, Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 1980; 62:282.</a></li><li><a class="nounderline abstract_t">Bogliun G, Beghi E, Crespi V, et al. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986; 74:284.</a></li><li><a class="nounderline abstract_t">Skillen AW, Pierides AM. Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy. Clin Chim Acta 1976; 72:245.</a></li><li><a class="nounderline abstract_t">Okesina AB, Donaldson D, Lascelles PT. Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy. J Clin Pathol 1991; 44:480.</a></li><li class="breakAll">Pettifor JM. Nutritional and drug-induced rickets and osteomalacia. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th, ASBMR, Favus MJ (Eds), Lippincott, Williams and Wilkins, Washington, DC 2006. p.330.</li><li><a class="nounderline abstract_t">Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 1970; 4:69.</a></li><li><a class="nounderline abstract_t">Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 1970; 4:73.</a></li><li><a class="nounderline abstract_t">Mosekilde L, Melsen F. Dynamic differences in trabecular bone remodeling between patients after jejunoileal bypass for obesity and epileptic patients receiving anticonvulsant therapy. Metab Bone Dis Relat Res 1980; 2:77.</a></li><li><a class="nounderline abstract_t">Weinstein RS, Bryce GF, Sappington LJ, et al. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984; 58:1003.</a></li><li><a class="nounderline abstract_t">Borgstedt AD, Bryson MF, Young LW, Forbes GB. Long-term administration of antiepileptic drugs and the development of rickets. J Pediatr 1972; 81:9.</a></li><li><a class="nounderline abstract_t">Fraser LA, Burneo JG, Fraser JA. Enzyme-inducing antiepileptic drugs and fractures in people with epilepsy: A systematic review. Epilepsy Res 2015; 116:59.</a></li><li><a class="nounderline abstract_t">Nicholas JM, Ridsdale L, Richardson MP, et al. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure 2013; 22:37.</a></li><li><a class="nounderline abstract_t">Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987; 33:139.</a></li><li><a class="nounderline abstract_t">Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001; 15:633.</a></li><li><a class="nounderline abstract_t">Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 2004; 5 Suppl 2:S3.</a></li><li><a class="nounderline abstract_t">Pack AM, Morrell MJ, McMahon DJ, Shane E. Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs. Epilepsy Behav 2011; 21:453.</a></li><li><a class="nounderline abstract_t">Mosekilde L, Hansen HH, Christensen MS, et al. Fractional intestinal calcium absorption in epileptics on anticonvulsant therapy. Short-term effect of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol. Acta Med Scand 1979; 205:405.</a></li><li><a class="nounderline abstract_t">Koch HU, Kraft D, von Herrath D, Schaefer K. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972; 13:829.</a></li><li><a class="nounderline abstract_t">Takahashi A, Onodera K, Shinoda H, Mayanagi H. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 2000; 82:82.</a></li><li><a class="nounderline abstract_t">Onodera K, Takahashi A, Sakurada S, Okano Y. Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 2002; 70:1533.</a></li><li><a class="nounderline abstract_t">Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 1990; 11:309.</a></li><li><a class="nounderline abstract_t">Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 2007; 16:22.</a></li><li><a class="nounderline abstract_t">Wu S, Legido A, De Luca F. Effects of valproic acid on longitudinal bone growth. J Child Neurol 2004; 19:26.</a></li><li><a class="nounderline abstract_t">Lambrinoudaki I, Kaparos G, Armeni E, et al. BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy. Eur J Neurol 2011; 18:93.</a></li><li><a class="nounderline abstract_t">Phabphal K, Geater A, Limapichart K, et al. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin. Epilepsia 2013; 54:249.</a></li><li><a class="nounderline abstract_t">Davie MW, Emberson CE, Lawson DE, et al. Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D. Q J Med 1983; 52:79.</a></li><li><a class="nounderline abstract_t">Hoikka V, Savolainen K, Alhava EM, et al. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 1981; 64:122.</a></li><li><a class="nounderline abstract_t">Bouillon R, Reynaert J, Claes JH, et al. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975; 41:1130.</a></li><li><a class="nounderline abstract_t">Hahn TJ, Hendin BA, Scharp CR, Haddad JG Jr. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972; 287:900.</a></li><li class="breakAll">Berry JL, Mawer EB, Walker DA, et al. Effect of antiepileptic drug therapy and exposure to sunlight on vitamin D status in institutionalized patients. In: Antiepileptic therapy: Chronic toxicity of antiepileptic drugs, Oxley J, Janz D, Meinardi H (Eds), Raven Press, New York 1983. p.185.</li><li><a class="nounderline abstract_t">Zhou C, Assem M, Tay JC, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006; 116:1703.</a></li><li><a class="nounderline abstract_t">Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115:177.</a></li><li><a class="nounderline abstract_t">Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008; 70:1586.</a></li><li><a class="nounderline abstract_t">Phabphal K, Geater A, Limapichat K, et al. Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy. Epilepsia 2013; 54:e94.</a></li><li><a class="nounderline abstract_t">Brämswig S, Zittermann A, Berthold HK. Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults. Calcif Tissue Int 2003; 73:356.</a></li><li><a class="nounderline abstract_t">Tjellesen L, Nilas L, Christiansen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol Scand 1983; 68:13.</a></li><li><a class="nounderline abstract_t">Kim SH, Lee JW, Choi KG, et al. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007; 10:291.</a></li><li><a class="nounderline abstract_t">Zhang X, Zhong R, Chen Q, et al. Effect of carbamazepine on the bone health of people with epilepsy: a systematic review and meta-analysis. J Int Med Res 2020; 48:300060520902608.</a></li><li><a class="nounderline abstract_t">Fan D, Miao J, Fan X, et al. Effects of valproic acid on bone mineral density and bone metabolism: A meta-analysis. Seizure 2019; 73:56.</a></li><li><a class="nounderline abstract_t">Zhong R, Chen Q, Zhang X, et al. Bone Mineral Density Loss in People With Epilepsy Taking Valproate as a Monotherapy: A Systematic Review and Meta-Analysis. Front Neurol 2019; 10:1171.</a></li><li><a class="nounderline abstract_t">Min L, Chunyan W, Biaoxue R. Effects of valproic acid on skeletal metabolism in children with epilepsy: a systematic evaluation and meta-analysis based on 14 studies. BMC Pediatr 2020; 20:97.</a></li><li><a class="nounderline abstract_t">Diemar SS, Sejling AS, Eiken P, et al. Effects of carbamazepine, eslicarbazepine, valproic acid and levetiracetam on bone microarchitecture in rats. Pharmacol Rep 2020; 72:1323.</a></li><li><a class="nounderline abstract_t">Guo Y, Lin Z, Huang Y, Yu L. Effects of valproate, lamotrigine, and levetiracetam monotherapy on bone health in newly diagnosed adult patients with epilepsy. Epilepsy Behav 2020; 113:107489.</a></li><li><a class="nounderline abstract_t">Whitney DG, Caird MS, Hurvitz EA, et al. Effect of levetiracetam and oxcarbazepine on 4-year fragility fracture risk among prepubertal and pubertal children with epilepsy. Epilepsia 2021; 62:2180.</a></li><li><a class="nounderline abstract_t">Shi KL, Guo JX, Zhao HM, et al. The effect of levetiracetam and oxcarbazepine monotherapy on thyroid hormones and bone metabolism in children with epilepsy: A prospective study. Epilepsy Behav 2020; 113:107555.</a></li><li><a class="nounderline abstract_t">Koo DL, Joo EY, Kim D, Hong SB. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res 2013; 104:134.</a></li><li><a class="nounderline abstract_t">Hall TJ, Higgins W, Tardif C, Chambers TJ. A comparison of the effects of inhibitors of carbonic anhydrase on osteoclastic bone resorption and purified carbonic anhydrase isozyme II. Calcif Tissue Int 1991; 49:328.</a></li><li><a class="nounderline abstract_t">Heo K, Rhee Y, Lee HW, et al. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia 2011; 52:1884.</a></li><li><a class="nounderline abstract_t">Koo DL, Nam H. Effects of zonisamide monotherapy on bone health in drug-naive epileptic patients. Epilepsia 2020; 61:2142.</a></li><li><a class="nounderline abstract_t">Harden CL. Menopause and bone density issues for women with epilepsy. Neurology 2003; 61:S16.</a></li><li><a class="nounderline abstract_t">Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004; 5 Suppl 2:S41.</a></li><li><a class="nounderline abstract_t">Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001; 58:1369.</a></li><li><a class="nounderline abstract_t">Fernandez H, Cooke M, Patel T. Epilepsy and lifestyle behaviors related to bone health. Epilepsia 2019; 60:2306.</a></li><li><a class="nounderline abstract_t">Mikati MA, Dib L, Yamout B, et al. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 2006; 67:2005.</a></li><li><a class="nounderline abstract_t">Sherk HH, Cruz M, Stambaugh J. Vitamin D prophylaxis and the lowered incidence of fractures in anticonvulsant rickets and osteomalacia. Clin Orthop Relat Res 1977; :251.</a></li><li><a class="nounderline abstract_t">Heaney RP. The case for improving vitamin D status. J Steroid Biochem Mol Biol 2007; 103:635.</a></li><li><a class="nounderline abstract_t">Collins N, Maher J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991; 78:113.</a></li><li><a class="nounderline abstract_t">Fernandez H, Mohammed HT, Patel T. Vitamin D supplementation for bone health in adults with epilepsy: A systematic review. Epilepsia 2018; 59:885.</a></li><li><a class="nounderline abstract_t">Lazzari AA, Dussault PM, Thakore-James M, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial. Epilepsia 2013; 54:1997.</a></li></ol></div><div id="topicVersionRevision">Topic 2063 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504780" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15217549" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bone disease in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123008" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epilepsy and bone health in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348155" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fracture risk is increased in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509233" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fracture risk associated with use of antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862179" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730381" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of five common fracture types in an institutional epileptic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4304972" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [Osteopathies in antiepileptic long-term therapy (preliminary report)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765648" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antiepileptic drug use and rates of hip bone loss in older men: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16218908" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epilepsy, osteoporosis and fracture risk - a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16529614" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176917" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Osteoporosis prevention, diagnosis, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901802" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Secondary osteoporosis: a review of the recent evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31749702" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bone Health in Rats With Temporal Lobe Epilepsy in the Absence of Anti-Epileptic Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8520716" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lifetime occupational physical activity and risk of hip fracture in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15679512" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18479399" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21220681" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23706474" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24780876" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19839772" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682661" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740572" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : An analysis of lifetime fractures in women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12102682" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk of extremity fractures in adult outpatients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123009" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bone health in pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28880998" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impaired bone and muscle development in young people treated with antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33962082" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effect of age when initiating anti-seizure medication therapy on fragility fracture risk for children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2721468" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of age-related fractures in patients with unprovoked seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26513212" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Changes in balance function with chronic antiepileptic drug therapy: A twin and sibling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10512774" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bone density and antiepileptic drugs: a case-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502911" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12011279" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of antiepileptic drugs on bone density in ambulatory patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020260" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antiepileptic drug-induced bone loss in young male patients who have seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697142" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668966" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7636651" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of carbamazepine and valproate on bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7892957" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11982890" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11580761" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265190" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bone mineral metabolism changes in epileptic children receiving valproic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9744632" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evaluation of bone mineral density in children receiving antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968482" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939856" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Adverse effects of antiepileptic drugs on bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057319" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Progressive bone deficit in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19486359" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bone mineral density in children, adolescents, and young adults with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559305" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anticonvulsant-induced bone disease: a plea for monitoring and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768830" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184613" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antiepileptic drug use increases rates of bone loss in older women: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053391" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716262" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Increased bone turnover in epileptic patients treated with carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460249" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3092278" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7468150" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Biochemical evidence for osteomalacia with carbamazepine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3811834" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Anticonvulsant drugs and bone metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10106" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2066427" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2066427" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5312062" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Osteomalacia with long-term anticonvulsant therapy in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5471772" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Disturbance of calcium metabolism by anticonvulsant drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dynamic differences in trabecular bone remodeling between patients after jejunoileal bypass for obesity and epileptic patients receiving anticonvulsant therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6725504" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5034878" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Long-term administration of antiepileptic drugs and the development of rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26354168" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Enzyme-inducing antiepileptic drugs and fractures in people with epilepsy: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23127777" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3306715" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524035" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123006" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pathophysiology of bone loss in patients receiving anticonvulsant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21704565" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/443080" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fractional intestinal calcium absorption in epileptics on anticonvulsant therapy. Short-term effect of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4509174" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10874595" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895104" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2252808" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110134" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Homocysteine and bone loss in epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15032379" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effects of valproic acid on longitudinal bone growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20500803" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23281616" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6603629" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7324878" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1206098" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4561667" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4561667" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16691293" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630458" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443309" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23586623" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874705" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6613523" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Does carbamazepine cause disturbances in calcium metabolism in epileptic patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224308" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32228127" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effect of carbamazepine on the bone health of people with epilepsy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31756600" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effects of valproic acid on bone mineral density and bone metabolism: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31787923" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Bone Mineral Density Loss in People With Epilepsy Taking Valproate as a Monotherapy: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32122313" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effects of valproic acid on skeletal metabolism in children with epilepsy: a systematic evaluation and meta-analysis based on 14 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32193854" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Effects of carbamazepine, eslicarbazepine, valproic acid and levetiracetam on bone microarchitecture in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33220583" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effects of valproate, lamotrigine, and levetiracetam monotherapy on bone health in newly diagnosed adult patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34250606" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effect of levetiracetam and oxcarbazepine on 4-year fragility fracture risk among prepubertal and pubertal children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33242769" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The effect of levetiracetam and oxcarbazepine monotherapy on thyroid hormones and bone metabolism in children with epilepsy: A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032070" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1782573" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A comparison of the effects of inhibitors of carbonic anhydrase on osteoclastic bone resorption and purified carbonic anhydrase isozyme II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692779" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32944954" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Effects of zonisamide monotherapy on bone health in drug-naive epileptic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504305" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Menopause and bone density issues for women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123011" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Treatment of anticonvulsant drug-induced bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559307" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31580495" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Epilepsy and lifestyle behaviors related to bone health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159108" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/608287" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Vitamin D prophylaxis and the lowered incidence of fractures in anticonvulsant rickets and osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222549" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The case for improving vitamin D status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1851568" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29399794" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Vitamin D supplementation for bone health in adults with epilepsy: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010637" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
